Home › Urothelial (Transitional Cell) Carcinoma › Massachusetts
Urothelial (Transitional Cell) Carcinoma clinical trials in Massachusetts
15 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #7, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- UMass Memorial Medical Center - University Campus, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06524544A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07090499Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Lahey Clinic, Burlington
- Lahey Clinic Peabody, Peabody
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- Mass General Brigham, Boston
- Brigham and Women's Hospital, Boston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05874921Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Massachusetts General Hospital, Boston
- University of Massachusetts Medical School, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218380Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06966024An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Research Site, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07720284A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- UMass Memorial Medical Center, Worcester
- University of Massachusetts Chan Medical School, Worcester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT04879329This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 2, 2026 · NCT06451497Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
- Dana-Farber Cancer Institute, Boston
RecruitingObservational study
Ages 65 and older · All sexes · Updated Feb 17, 2026 · NCT06138561Sacituzumab Govitecan Plus EV in Metastatic UC
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT04724018SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.